High sampling resolution optical coherence tomography reveals potential concurrent reductions in ganglion cell-inner plexiform and inner nuclear layer thickness but not in outer retinal thickness in glaucoma.
Journal
Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)
ISSN: 1475-1313
Titre abrégé: Ophthalmic Physiol Opt
Pays: England
ID NLM: 8208839
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
28
10
2022
received:
14
06
2022
accepted:
30
10
2022
pubmed:
24
11
2022
medline:
15
12
2022
entrez:
23
11
2022
Statut:
ppublish
Résumé
To analyse optical coherence tomography (OCT)-derived inner nuclear layer (INL) and outer retinal complex (ORC) measurements relative to ganglion cell-inner plexiform layer (GCIPL) measurements in glaucoma. Glaucoma participants (n = 271) were categorised by 10-2 visual field defect type. Differences in GCIPL, INL and ORC thickness were calculated between glaucoma and matched healthy eyes (n = 548). Hierarchical cluster algorithms were applied to generate topographic patterns of retinal thickness change, with agreement between layers assessed using Cohen's kappa (κ). Differences in GCIPL, INL and ORC thickness within and outside GCIPL regions showing the greatest reductions and Spearman's correlations between layer pairs were compared with 10-2 mean deviation (MD) and pattern standard deviation (PSD) to determine trends with glaucoma severity. Glaucoma participants with inferior and superior defects presented with concordant GCIPL and INL defects demonstrating mostly fair-to-moderate agreement (κ = 0.145-0.540), which was not observed in eyes with no or ring defects (κ = -0.067-0.230). Correlations (r) with MD and PSD were moderate and weak in GCIPL and INL thickness differences, respectively (GCIPL vs. MD r = 0.479, GCIPL vs. PSD r = -0.583, INL vs. MD r = 0.259, INL vs. PSD r = -0.187, p = <0.0001-0.002), and weak in GCIPL-INL correlations (MD r = 0.175, p = 0.004 and PSD r = 0.154, p = 0.01). No consistent patterns in ORC thickness or correlations were observed. In glaucoma, concordant reductions in macular INL and GCIPL thickness can be observed, but reductions in ORC thickness appear unlikely. These findings suggest that trans-synaptic retrograde degeneration may occur in glaucoma and could indicate the usefulness of INL thickness in evaluating glaucomatous damage.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
46-63Informations de copyright
© 2022 The Authors. Ophthalmic and Physiological Optics published by John Wiley & Sons Ltd on behalf of College of Optometrists.
Références
Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):1693-1703
pubmed: 29610852
Invest Ophthalmol Vis Sci. 2022 Jan 3;63(1):18
pubmed: 35024761
Clin Ophthalmol. 2020 Jun 15;14:1591-1599
pubmed: 32606574
Biomed Opt Express. 2013 Jun 14;4(7):1133-52
pubmed: 23847738
J Comp Neurol. 1990 Oct 1;300(1):5-25
pubmed: 2229487
Am J Ophthalmol. 2006 Jan;141(1):24-30
pubmed: 16386972
J Comp Neurol. 2019 Jan 1;527(1):87-116
pubmed: 27447117
Sci Rep. 2020 Oct 28;10(1):18527
pubmed: 33116253
Br J Ophthalmol. 2011 Jan;95(1):131-41
pubmed: 20956277
Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):3086-3099
pubmed: 28632847
Ophthalmology. 2021 Oct;128(10):1405-1416
pubmed: 33722636
Invest Ophthalmol Vis Sci. 2011 Feb 16;52(2):940-6
pubmed: 20881293
Front Neurosci. 2018 May 29;12:363
pubmed: 29896087
Invest Ophthalmol Vis Sci. 2013 Jul 22;54(7):4934-40
pubmed: 23761080
Science. 1974 Oct 4;186(4158):47-9
pubmed: 4417736
Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
PLoS One. 2021 Feb 25;16(2):e0247401
pubmed: 33630899
Am J Ophthalmol. 2019 Dec;208:166-177
pubmed: 31078539
Science. 1976 Oct 8;194(4261):193-5
pubmed: 959847
Transl Vis Sci Technol. 2020 Sep 14;9(10):15
pubmed: 32974087
Ophthalmol Glaucoma. 2020 Jul - Aug;3(4):274-287
pubmed: 33012332
Lancet. 2017 Nov 11;390(10108):2183-2193
pubmed: 28577860
Ophthalmic Physiol Opt. 2023 Jan;43(1):46-63
pubmed: 36416369
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3496-504
pubmed: 26047040
Arch Ophthalmol. 2009 Jul;127(7):875-81
pubmed: 19597108
J Comp Neurol. 2007 Nov 1;505(1):131-46
pubmed: 17729268
Prog Retin Eye Res. 2013 Jan;32:1-21
pubmed: 22995953
Neuroscience. 2002;109(1):157-68
pubmed: 11784707
PLoS One. 2015 Jun 12;10(6):e0130175
pubmed: 26066021
Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4241-4248
pubmed: 31618760
Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4815-23
pubmed: 27623336
Invest Ophthalmol Vis Sci. 2012 Sep 12;53(10):6102-8
pubmed: 22893674
Invest Ophthalmol Vis Sci. 2014 Feb 03;55(2):632-49
pubmed: 24370831
Invest Ophthalmol Vis Sci. 2020 Sep 1;61(11):16
pubmed: 32915981
Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4896-4903
pubmed: 31752019
Vision Res. 2007 Oct;47(22):2901-11
pubmed: 17320143
Br J Ophthalmol. 2019 Sep;103(9):1217-1222
pubmed: 30385436
Invest Ophthalmol Vis Sci. 2012 Mar 09;53(3):1271-5
pubmed: 22222509
Am J Ophthalmol. 2017 Apr;176:148-156
pubmed: 28130041
Ophthalmology. 2019 Jul;126(7):980-988
pubmed: 30858023
Ophthalmology. 2017 Aug;124(8):1218-1228
pubmed: 28461015
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):2
pubmed: 32150251
Int J Integr Care. 2020 Aug 07;20(3):5
pubmed: 32863803
Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):952-61
pubmed: 24398089
Am J Ophthalmol. 2020 Jan;209:117-131
pubmed: 31469999
Invest Ophthalmol Vis Sci. 2011 Nov 11;52(12):8769-79
pubmed: 21989721
J Clin Med. 2020 May 16;9(5):
pubmed: 32429480
Invest Ophthalmol Vis Sci. 2011 Jun 06;52(7):3943-54
pubmed: 21421869
Arch Ophthalmol. 2011 Dec;129(12):1529-36
pubmed: 22159673
Am J Ophthalmol. 2018 Aug;192:1-9
pubmed: 29750944
Invest Ophthalmol Vis Sci. 2012 Apr 30;53(4):2424-30
pubmed: 22427540
Invest Ophthalmol Vis Sci. 2016 Feb;57(2):502-7
pubmed: 26873511
Mol Brain. 2014 Aug 13;7:53
pubmed: 25116810
J Glaucoma. 2017 May;26(5):423-429
pubmed: 28169924
Invest Ophthalmol Vis Sci. 2022 May 2;63(5):36
pubmed: 35622354
PLoS One. 2018 Dec 31;13(12):e0209610
pubmed: 30596720
Ophthalmology. 2011 Feb;118(2):241-8.e1
pubmed: 20920824
Clin Exp Optom. 2013 May;96(3):310-32
pubmed: 23464379
PLoS One. 2017 Aug 3;12(8):e0182404
pubmed: 28771565
J Comp Neurol. 1990 Feb 22;292(4):497-523
pubmed: 2324310
Sci Rep. 2021 Jan 12;11(1):558
pubmed: 33436715
J Comp Neurol. 2019 Jan 1;527(1):159-173
pubmed: 27411041
Clin Exp Optom. 2019 May;102(3):291-299
pubmed: 30499141
Biomed Opt Express. 2020 Nov 10;11(12):7079-7095
pubmed: 33408981
Water Resour Res. 2014 Dec;50(12):9484-9513
pubmed: 25745272
Am J Ophthalmol. 2008 Feb;145(2):343-53
pubmed: 18078852
Sci Rep. 2017 Jul 17;7(1):5543
pubmed: 28717139
Ophthalmic Physiol Opt. 2022 Sep;42(5):948-964
pubmed: 35598146
Mol Vis. 2011 Feb 03;17:355-79
pubmed: 21311605
PLoS One. 2015 May 15;10(5):e0125957
pubmed: 25978420
PLoS One. 2018 Apr 19;13(4):e0196112
pubmed: 29672563
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4863-4876
pubmed: 28973333
PLoS One. 2015 Dec 04;10(12):e0144341
pubmed: 26637126
Invest Ophthalmol Vis Sci. 2011 Oct 04;52(11):7872-9
pubmed: 21873658
Ophthalmic Physiol Opt. 2018 Nov;38(6):584-595
pubmed: 30575075
Invest Ophthalmol Vis Sci. 2000 Mar;41(3):741-8
pubmed: 10711689
Transl Vis Sci Technol. 2022 May 2;11(5):13
pubmed: 35575777
Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4211-4217
pubmed: 28837723
Acta Ophthalmol. 2015 Jun;93(4):355-61
pubmed: 25487761
Sci Rep. 2019 Dec 19;9(1):19440
pubmed: 31857628
PLoS One. 2013 Aug 19;8(8):e72282
pubmed: 23977271
Ann Epidemiol. 2007 Jan;17(1):27-35
pubmed: 17027287
Anesth Analg. 2018 May;126(5):1763-1768
pubmed: 29481436
Transl Vis Sci Technol. 2022 Apr 1;11(4):18
pubmed: 35438719
Ophthalmology. 2021 Jan;128(1):P71-P150
pubmed: 34933745
Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3099-106
pubmed: 15326126
Medicine (Baltimore). 2016 Nov;95(46):e5441
pubmed: 27861391
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):20
pubmed: 32301971
Clin Exp Optom. 2017 May;100(3):214-226
pubmed: 27728957